Ivix

Ivix Overview

Founded 2012
Founded
Status Acquired/​Merged
Latest Deal Type M&A
Latest Deal Amount $6.2M
Latest Deal Amount

Ivix General Information

Description

Developer of drugs designed to treat female sexual and reproductive dysfunctions. The company's drugs are produced using innovations in molecular biology and physiology which changes the activity of genes involved in the metabolism of certain neurotransmitters in the brain, enabling women to treat sexual disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Table Lane 6
  • Moscow
  • Russia
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ivix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 25-Sep-2018 $6.2M 000.00 Completed Generating Revenue
1. Early Stage VC 01-Jan-2013 Completed Startup

Ivix Executive Team (3)

Name Title Board Seat Contact Info
Dmitry Golikov MD Chief Executive Officer & General Manager
Mikhail Lomonosov Ph.D Director for Science and Production
Elena Kasimova Director, Business Development & Board Member

Ivix Board Members (1)

Name Representing Role Since
Elena Kasimova Self Director, Business Development & Board Member 000 0000

Ivix Former Investors (1)

To view Ivix‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Russian Venture Company Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial